Ponentes

Jasmini Alagaratnam, PhD
Jasmini Alagaratnam, PhD
Dr Jasmini Alagaratnam is a clinical research fellow at Imperial College London and a specialty trainee in GU and HIV Medicine, at St Mary’s Hospital, London. She is undertaking a PhD; the overarching theme of her PhD thesis is investigating neuronal activation in the central nervous system in the context of HIV, using biomarkers (blood and cerebrospinal fluid), and imaging (MRI and PET-CT). Her other areas of clinical and research interests include HIV reservoir and eradication strategies, the management of indeterminate HIV test results in the context of PrEP/PEP and HIV in pregnancy.
Gabriele Arendt, MD.
Gabriele Arendt, MD.

Gabriele Arendt, MD, is associate Professor in Neurology, University Hospital of Duesseldorf, Germany. Since 1987, she chairs the Neuro-AIDS out-patient department of the hospital with about 1100 patients/year. The Duesseldorf HIV cohort comprises by now almost 5000 patients. She acquired her medical and scientific degrees in the University of Duesseldorf, then specialised on psychiatry and later on neurology and neurophysiology. Her scientific interest focuses on motor abnormalities in HIV-positive patients, disturbances of the dopaminergic pathways in these patients and on the significance of cytokines for the neuropathogenesis of HIV-associated dementia.

She is in the editorial boards of the Journal of NeuroVirology, the Journal of NeuroAIDS and of Neurobehavioral HIV Medicine, an open access journal. She is a member of the German Aids Society. She has written more than 150 papers, HIV/AIDS chapters in most of the German standard textbooks and three books. She has designed and conducted many national multicenter studies and participated in international studies.

Francesc Artigas
Francesc Artigas
Francesc Artigas is Chair of the Department of Neurochemistry and Neuropoharmacology at the Insitut d’Investigacions Biomèdiques de Barcelona, (Spanish Research Council, CSICIDIBAPS). He is member of the executive committee of CIBERSAM, a Government‐supported network of excellence groups on Mental Health in Spain, where he coordinates the Therapeutic Innovation Program. He leads a research group on Systems Neuropharmacology and his main scientific interest is the study of brain circuits involved in the pathophysiology and treatment of major depression and schizophrenia. He has supervised 24 PhD students and 23 postdoctoral positions. He has served in Scientific Societies as member of the Executive Committee (European College of Neuropsychopharmacology, ECNP), Councilor (International College of Neuropsychopharmacology, CINP), President (Spanish Society for Neuroscience) or vice‐President (International Society for Serotonin Research, ISSR). He is or has been member of the Editorial Boards of several scientific journals. He has published over 230 papers in peerreviewed journals, cited ~14.000 times (h = 65; Web of Science). He also received several Awards, including the ECNP Neuropsychopharmacology Award in 2015, the most prestigious European Award in the field, being the first Spanish scientist to receive the Award.
Andrea Calcagno, MD, DTM&H.
Andrea Calcagno, MD, DTM&H.

He is temporary Assistant Professor at the University of Torino (Department of Medical Sciences, Infectious Diseases). Infectious Diseases Specialist (University of Torino, Italy); Diploma in Tropical Medicine and Hygiene (Mahidol University, Bangkok, Thailand). He is member of the Panel of the Italian Guidelines on the Use of Antiretrovirals and Management of patients living with HIV.

He has experience as a Clinicians in Infectious Diseases and Tropical Medicine (Sudan, Thailand, Burundi); several phase II, III and IV studies in antiretroviral treatment trials.

His main field of interest is the clinical pharmacology and pharmacogenetics of anti-infective agents (antiretroviral, antibiotic, antifungals) and the central nervous system complication of HIV-infection.

Paola Cinque, MD, Ph. D.
Paola Cinque, MD, Ph. D.

She is currently working as senior physician at the Department of Infectious Diseases and responsible of the Neurovirology Research Unit at the Research Division of Immunology, Transplantation and Infectious Diseases of San Raffaele Scientific Institute, Milan, Italy, and as contract Professor of Infectious Diseases at San Raffaele University.

Her research group is mainly involved in studies on HIV Infection of the Central Nervous System, Progressive Multifocal Leukoencephalopathy and other HIV-associated CNS complications.

She is a panel member of the Italian HIV Treatment Guidelines, of the EACS Co-morbidities and of the Opportunistic Infections Guidelines, and of the NIH/CDC/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections.in HIV-Infected Adults and Adolescents.

Guida da Ponte, Ph. D.
Guida da Ponte, Ph. D.

Guida da Ponte is a Psychiatry Consultant, Coordinator of Liaison Psychiatry Unit, in Centro Hospitalar Barreiro-Montijo, located in the suburban area of Lisbon, Portugal. One of the major fields of practice is with HIV patients with a psychiatric outpatient clinic dedicated to this condition. Author of scientific publications, mainly in the areas of neurocognitive disorders, depression, anxiety and psychopharmacology and antiretroviral interactions. Other major area of interest is Psycho-Oncology, as PhD student of Medical School of Lisbon, University of Lisbon.

Fiona Lampe, PhD
Fiona Lampe, PhD
Fiona Lampe, PhD is Senior Lecturer in Epidemiology and Biostatistics, at the Research Department of Infection and Population Health, University College London, UK. Her areas of work include HIV-related observational research studies and clinical trials. Her main research interests include clinical care and prognosis of HIV; the impact of gender, region, and socio-economic status; mental health and quality of life; HIV prevention.
Scott Letendre, MD.
Scott Letendre, MD.

Scott Letendre, M.D., is Professor of Medicine in Residence in the Division of Infectious Diseases at the University of California, San Diego (UCSD). He graduated from Georgetown University School of Medicine and, following his residency in internal medicine at the Naval Medical Center in San Diego, he completed fellowships in Infectious Disease Medicine at Duke University and in Neurologic HIV Research at UCSD. At UCSD, Dr. Letendre performs translational, patient-oriented research of the central nervous system complications of chronic infections, including HIV, HCV, and CMV. As part of a multidisciplinary research team, he conducts treatment trials of neurocognitively impaired individuals and analyzes their response to therapy as well as studies of the pharmacokinetics of antiretrovirals, the effect of comorbidities, and biomarker correlates of disease. Dr. Letendre is also an investigator in the UCSD unit of the AIDS Clinical Trials Group.

He participates in several international research projects, including projects based in China, India, Zambia, and Romania. Dr. Letendre balances his research activities with regular, clinical outpatient and inpatient care of people living with HIV and other infectious diseases. Dr. Letendre also teaches in the Microbiology course at the UCSD School of Medicine and chairs the UCSD Institutional Biosafety Committee. Dr. Letendre has published in several peer-reviewed journals including AIDS, Clinical Infectious Diseases, Journal of Infectious Diseases, Neurology, Journal of Virology, Journal of Neurovirology, Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, and Journal of Neuroimmunology.

Jose A. Muñoz-Moreno, Ph. D.
Jose A. Muñoz-Moreno, Ph. D.

Jose A. Muñoz-Moreno is a clinician and researcher at the Lluita contra la SIDA Foundation, located in the Germans Trias i Pujol University Hospital, in Barcelona (Catalonia, Spain). He earned the Ph.D. degree in Neurosciences in 2012 (Cum Laude), and currently he is also a collaborating professor with the Universitat de Barcelona (UB) and the Universitat Autònoma de Barcelona (UAB).

Muñoz-Moreno is involved in projects that address psychology and the human behaviour associated with HIV infection. In terms of study, he mostly investigates the neurocognitive features of HIV infection, the impact of HIV and antiretroviral treatments on quality of life and emotional status, and adherence to antiretroviral therapy.

Muñoz-Moreno’s recent work particularly focuses on assessment methods to detect HIV-related neurocognitive changes and the current profile of neurocognitive impairment in people living with HIV infection.

Brendan Payne, PhD
Brendan Payne, PhD
Dr. Brendan Payne is a principle investigator in the Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle University, UK. He holds honorary clinical appointments in the Department of Infection and Tropical Medicine and the Department of Microbiology at Newcastle-upon-Tyne Hospitals. His doctoral research was undertaken in the laboratory of Professor Patrick Chinnery, and focussed on the characterisation of somatic mitochondrial DNA mutations in the setting of anti-retroviral therapy. He is actively involved in clinical translational research as well as laboratory studies of the patho-mechanisms of mitochondrial dysfunction in aging. This involves the development of novel histological and molecular techniques to characterise mitochondrial defects. He is particularly interested in the natural history of mitochondrial DNA mutations in aging and how this may be altered, either detrimentally (such as in anti-retroviral treated HIV), or therapeutically. His principle research funder is Wellcome: through a personal fellowship, and as a PI in the WCMR.
Ignacio Pérez-Valero, MD, Ph. D.
Ignacio Pérez-Valero, MD, Ph. D.
Ignacio Pérez-Valero MD PhD is a 41 years-old Consultant Physician of Internal Medicine at the La Paz University Hospital and a Senior Clinical Researcher at the IDIPAZ Research Institute (Madrid, Spain).
Daniel Podzamczer, Phd
Daniel Podzamczer, Phd
Medical Degree: University of Buenos Aires, Argentina (1977); Medicine Ph Degree: University of Barcelona, Spain (1991); Residence in Internal Medicine: Hospital Universitari de Bellvitge. Barcelona. Spain (1981-1984); Chief, AIDS Unit. Hospital Universitari de Bellvitge (1989-) Main research area: Antiretroviral therapy (efficacy, metabolic complications, lipodystrophy); ARV concentrations and viral activity in reservoirs (CNS and semen), AIDS related complications: opportunistic infections and Kaposi’s sarcoma. Member of Expert Panels for Recommendations of Prevention and Treatment of Opportunistic Infections (NIH/CDC/IDSA), Antiretroviral Threrapy (GESIDA, Spain), Neurocognitive Disorders (GESIDA, Spain). Co-author of more than 280 publications in peer-review Journals (including N Engl J Med, Ann Intern Med, J Infect Dis, Clin Infect Dis, AIDS, JAIDS, etc). Editorial scientific board of several Internal Medicine, Infectious Disease and HIV/AIDS Journals: AIDS Reviews, HIV Medicine, and others. Peer-reviewer of papers for Journals such as Lancet, Lancet Infectious Diseases, Lancet HIV, Clin Infect Dis, J Antimicrob Chemother, BMC Infect Dis, , HIV Med, Antiviral Ther, AIDS Res Human Retrovir among others.
Reuben Robbins, MD
Reuben Robbins, MD
Reuben N. Robbins is an Assistant Professor of Clinical Psychology (in Psychiatry) at Columbia University and a former postdoctoral fellow at theHIV Center. He received his Ph.D. in Clinical Psychology from the Graduate School of Arts and Sciences at Fordham University and completed his internship at the University of Florida. Dr. Robbins brings his expertise in individual, couples and group psychotherapy, as well as adult and child neuropsychological assessment to the HIV Center. Drawing on his clinical work, Dr. Robbins is interested in developing and testing technologically-based interventions that can promote positive health outcomes among those living with HIV. He is a Co-Investigator on the "Masivukeni: A Multimedia ART Adherence Intervention for Resource-Limited Settings" study, which is an intervention delivered via computer using multimedia and interactive activities to engage patients and counselors. Masivukeni aims to empower HIV patients to be active participants in their HIV treatment and consistently take their HIV medications, and enable counselors to deliver consistent health messages and effectively engage patients in learning about HIV and antiretroviral therapy. Dr. Robbins is also the Principal Investigator on the study "Using Smartphones to Improve HIV Outcomes: An App to Detect Neurocognitive Impairment." This project is testing out a novel, smartphone app that simplifies and automates components of the screening process for HIV-associated neurocognitive impairment. Dr. Robbins hopes this app can empower all levels of HIV care providers to conduct neurocognitive screenings and make routine screening for neurocognitive impairment easier and more accessible to HIV clinics in resource-limited settings. Dr. Robbins is also actively involved in the NY & NJ AIDS Training and Education Center and the Columbia University HIV Mental Health Training Project. Dr. Robbins provides training to HIV care providers throughout New York State on the psychosocial and neuropsychiatric aspects of HIV.
Annemiek Shadé, MD, PhD
Annemiek Shadé, MD, PhD

Annemiek Schadé works as a psychiatrist since2005 at the HIV Expert and Treatment Center on HIV and Mental Health and as a consultant at the University Hospital VU Medical Center in Amsterdam. She is a trainer for medical residents psychiatry and interns. The past years, she provided trainings on HIV and Mental Health in former Soviet Republics and new EU-countries. She published a study book and (research) articles on HIV and Mental Health.

Sanne van Luenen, Phd
Sanne van Luenen, Phd
Sanne van Luenen is a nurse and psychologist. She works as a postdoctoral researcher at Leiden University and Leiden University Medical Center. She conducts several eHealth studies. In her PhD research she investigated the effectiveness of a guided online intervention for people living with HIV and depressive symptoms. The intervention is being implemented at the moment.
Milton Wainberg, MD
Milton Wainberg, MD
Milton Wainberg is Professor of Clinical Psychiatry and Director of Global Mental Health Research in the Department of Psychiatry, Columbia University. He is Director of the NIMH-funded Columbia University Global Mental Health Implementation Science T32-Post Doctoral Fellowship, NIMH/Fogarty International-funded Portuguese-speaking African countries Mental Health Implementation Research Training Program, Founding Chair of the Caucus of Global Mental Health and Psychiatry of the American Psychiatric Association, and Medical Director of the Columbia University HIV Mental Health Training Project. Dr. Wainberg is the Chair of the Mental Health HIV Clinical Guidelines Committee of the New York State Department of Health/AIDS Institute, and has been Principal investigator or investigator of multiple NIMH, NIAAA, NIDA and CDC studies addressing the intersection of mental illness, substance use and abuse, HIV-associated fatigue, sexual compulsivity and HIV prevention and adherence to care, as well as the stigma and discrimination associated with mental illness, HIV, race/ethnicity and being a sexual minority. Dr. Wainberg is the Principal Investigators of the NIMH-funded PRIDE sSA - Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence-based Practices: sub-Saharan Africa which comprises a large scale up study delivering comprehensive efficacious and sustainable psychiatric care in three Provinces of Mozambique, and capacity building of a collaborative research network that will train service providers, investigators and policy-makers from Botswana, Malawi, Mozambique, South Africa, Zambia.  His research to practice work aims to decrease the global mental health treatment and research gaps.
Alan Winston, MD.
Alan Winston, MD.
Dr.Winston is a Clinical Senior Lecturer in Communicable Diseases at Imperial College, London and Consultant Physician in HIV and GU Medicine at St. Mary’s Hospital, London. Dr.Winston is a clinical researcher with an MD in clinical pharmacology and runs a portfolio of clinical trials assessing non-infectious co-morbidities, including cerebral function, in relation to HIV disease with a focus on antiretroviral pharmacokinetics and pharmacodynamics in sanctuary sites.

Ver el programa